CS35392A3 - Inhaling preparation for asthma treating - Google Patents

Inhaling preparation for asthma treating Download PDF

Info

Publication number
CS35392A3
CS35392A3 CS92353A CS35392A CS35392A3 CS 35392 A3 CS35392 A3 CS 35392A3 CS 92353 A CS92353 A CS 92353A CS 35392 A CS35392 A CS 35392A CS 35392 A3 CS35392 A3 CS 35392A3
Authority
CS
Czechoslovakia
Prior art keywords
furosemide
inhaled
asthma
treatment
combination
Prior art date
Application number
CS92353A
Other languages
Czech (cs)
English (en)
Inventor
Sebastiano Prof Bianco
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of CS35392A3 publication Critical patent/CS35392A3/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A61K31/621—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CS92353A 1991-02-09 1992-02-07 Inhaling preparation for asthma treating CS35392A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP91101817 1991-02-09

Publications (1)

Publication Number Publication Date
CS35392A3 true CS35392A3 (en) 1992-08-12

Family

ID=8206392

Family Applications (1)

Application Number Title Priority Date Filing Date
CS92353A CS35392A3 (en) 1991-02-09 1992-02-07 Inhaling preparation for asthma treating

Country Status (15)

Country Link
US (2) US5366967A (pt)
EP (1) EP0499142A3 (pt)
JP (1) JPH0680587A (pt)
KR (1) KR920016093A (pt)
AU (1) AU652798B2 (pt)
BR (1) BR9200430A (pt)
CA (1) CA2060954A1 (pt)
CS (1) CS35392A3 (pt)
HU (1) HU209609B (pt)
IE (1) IE920426A1 (pt)
IL (1) IL100897A0 (pt)
MX (1) MX9200570A (pt)
NO (1) NO920503L (pt)
NZ (1) NZ241541A (pt)
ZA (1) ZA92891B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0499143B1 (en) * 1991-02-09 1999-05-06 B.S.D. BIO SCIENCE DEVELOPMENT SNC Di OMINI C. & ZUCCARI G. Anti-reactive anti-asthmatic activity of acetylsalicylic acid by inhalation
HU219899B (hu) 1995-04-14 2001-09-28 Glaxo Wellcome Inc. Inhalálóberendezés flutikaszon-propionát adagolására mért dózisban
TR199701170T1 (xx) 1995-04-14 1998-02-21 Glaxo Wellcome Inc. Beklometazon dipropionat i�in �l��lm�� doz inhaleri.
HU219900B (hu) 1995-04-14 2001-09-28 Glaxo Wellcome Inc. Mért dózist adagoló inhalálóberendezés
TR199701169T1 (xx) * 1995-04-14 1998-03-21 Glaxo Wellcome Inc. Salmeterol i�in �l��lm�� doz inhaleri.
DE10034802A1 (de) * 2000-07-18 2002-01-31 Bayer Ag Stabile Salze von O-Acetylsalicylsäure mit basischen Aminosäuren
US7028990B2 (en) * 2001-05-11 2006-04-18 Ray Robert Shorey Temporary rooftop and stairway safety rail system
DE10223932A1 (de) * 2002-05-29 2003-12-18 Rudolf Wank Verwendung von Diuretika zur Behandlung von Schwellungen
DE102005025283A1 (de) * 2005-06-02 2006-12-07 Bayer Healthcare Ag Stabiler Wirkstoffkomplex von Salzen der o-Acetylsalicylsäure mit basischen Aminosäuren und Glycin
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
AU2013388034B2 (en) 2013-04-30 2019-08-15 Aspeya US Inc. Dry powder formulations and methods of use
CN112656780A (zh) 2014-02-20 2021-04-16 奥迪托皮克股份有限公司 用于吸入的干粉制剂
WO2017058370A1 (en) * 2015-09-30 2017-04-06 Rutgers, The State University Of New Jersey Carbonic anhydrase enzymes for regulating mast cell hematopoiesis and type 2 inflammation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888343A (en) * 1986-09-15 1989-12-19 Bristol-Myers Company Pharmaceutical compositions for relief of dysmenorrhea and/or premenstrual syndrome and process
JPH0720862B2 (ja) * 1989-01-27 1995-03-08 ヘキスト・アクチエンゲゼルシヤフト 吸入用喘息治療剤
DE3907414A1 (de) * 1989-03-08 1990-09-13 Hoechst Ag Die anwendung inhalierter schleifendiuretika zur behandlung von allergen-induzierten nasalen reaktionen
DE4010536A1 (de) * 1990-04-02 1991-10-10 Boehringer Mannheim Gmbh Pharmazeutische waessrige loesung von 4-(2-(benzolsulfonylamino)-ethyl)-phenoxyessigsaeure

Also Published As

Publication number Publication date
IE920426A1 (en) 1992-08-12
AU1077092A (en) 1992-08-13
ZA92891B (en) 1992-12-30
EP0499142A2 (en) 1992-08-19
HUT60438A (en) 1992-09-28
US5750559A (en) 1998-05-12
EP0499142A3 (en) 1993-05-05
JPH0680587A (ja) 1994-03-22
NZ241541A (en) 1996-05-28
NO920503L (no) 1992-08-10
MX9200570A (es) 1994-07-29
IL100897A0 (en) 1992-11-15
BR9200430A (pt) 1992-10-13
HU209609B (en) 1994-09-28
CA2060954A1 (en) 1992-08-10
US5366967A (en) 1994-11-22
HU9200390D0 (en) 1992-04-28
AU652798B2 (en) 1994-09-08
NO920503D0 (no) 1992-02-07
KR920016093A (ko) 1992-09-24

Similar Documents

Publication Publication Date Title
CS35392A3 (en) Inhaling preparation for asthma treating
US6051566A (en) Anti-reactive anti-asthmatic activity of non-steroidal anti-inflammatory drugs by inhalation
Stapleton et al. Hypercholesterolemia and microvascular dysfunction: interventional strategies
Ong et al. Effects of inhaled furosemide on exertional dyspnea in chronic obstructive pulmonary disease
Matera et al. Safety considerations with dual bronchodilator therapy in COPD: an update
Rendell et al. Assessment of N-acetylcysteine as a therapy for phosgene-induced acute lung injury
Huang et al. Effect of surfactant and budesonide on the pulmonary distribution of fluorescent dye in mice
Newton et al. Nebulized furosemide for the management of dyspnea: does the evidence support its use?
O'Connor et al. Nonbronchodilator effects of inhaled beta 2 agonists. Greater protection against adenosine monophosphate-than methacholine-induced bronchoconstriction in asthma.
Crimi et al. Effect of indomethacin on adenosine-induced bronchoconstriction
Groot et al. Effect of inhaled beclomethasone and nedocromil sodium on bronchial hyperresponsiveness to histamine and distilled water
King et al. Hypertrophic osteoarthropathy effectively treated with zoledronic acid
Buyuktiryaki et al. Therapeutic and preventative effects of ankaferd blood stopper in an experimental necrotizing enterocolitis model
Liu et al. Urolithin A alleviates early brain injury after subarachnoid hemorrhage by regulating the AMPK/mTOR pathway-mediated autophagy
Wang et al. Targeting reactive oxygen species by edaravone inhalation in a rat hyperoxic lung injury model: role of inflammasome
Subbarao et al. Protection by budesonide and fluticasone on allergen-induced airway responses after discontinuation of therapy
Massie Exercise-induced asthma in children
Randell et al. Safety of formoterol after cumulative dosing via Easyhaler® and Aerolizer®
Ok et al. Analgesic effects of intravenous curcumin in the rat formalin test
EP0919229A2 (en) Anti-reactive anti-asthmatic activity of non-steroidal anti-inflammatory drugs by inhalation
Sestini et al. Protective effect of inhaled lysine acetylsalicylate on allergen-induced early and late asthmatic reactions
Lange et al. Heterogeneity of the effects of combined nitric oxide synthase inhibition on organ perfusion in ovine sepsis
Boulet et al. Inhibitory Effect of BAY X 7195, a CYS Leukotriene 1 Receptor Antagonist, on Allergen-Induced Asthmatic Responses
Guo et al. Effect of solasodine on mast cell-mediated OVA (ovalbumin)-induced airway inflammation in asthma via the Fyn-Lyn-Syk pathway
Rupniewska-Ładyko Ketamine—A unique adjuvant drug in pain treatment